首页> 美国卫生研究院文献>Scientific Reports >Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection
【2h】

Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection

机译:人诱导多能干细胞衍生的肝细胞样细胞作为人乙型肝炎病毒感染的体外模型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In order to understand the life cycle of hepatitis B virus (HBV) and to develop efficient anti-HBV drugs, a useful in vitro cell culture system which allows HBV infection and recapitulates virus-host interactions is essential; however, pre-existing in vitro HBV infection models are often problematic. Here, we examined the potential of human induced-pluripotent stem (iPS) cell-derived hepatocyte-like cells (iPS-HLCs) as an in vitro HBV infection model. Expression levels of several genes involved in HBV infection, including the sodium taurocholate cotransporting polypeptide (NTCP) gene, were gradually elevated as the differentiation status of human iPS cells proceeded to iPS-HLCs. The mRNA levels of these genes were comparable between primary human hepatocytes (PHHs) and iPS-HLCs. Following inoculation with HBV, we found significant production of HBV proteins and viral RNAs in iPS-HLCs. The three major forms of the HBV genome were detected in iPS-HLCs by Southern blotting analysis. Anti-HBV agents entecavir and Myrcludex-B, which are a nucleoside analogue reverse transcriptase inhibitor and a synthetic pre-S1 peptide, respectively, significantly inhibited HBV infection in iPS-HLCs. These data demonstrate that iPS-HLCs can be used as a promising in vitro HBV infection model.
机译:为了了解乙型肝炎病毒(HBV)的生命周期并开发有效的抗HBV药物,有用的体外细胞培养系统必须能够使HBV感染并概括病毒与宿主之间的相互作用。但是,既存的体外HBV感染模型通常是有问题的。在这里,我们检查了人诱导多能干(iPS)细胞来源的肝样细胞(iPS-HLCs)作为体外HBV感染模型的潜力。随着人iPS细胞的分化状态发展到iPS-HLC,涉及HBV感染的几种基因(包括牛磺胆酸钠共转运多肽(NTCP)基因)的表达水平逐渐升高。这些基因的mRNA水平在原代人肝细胞(PHH)和iPS-HLC之间是可比的。接种HBV后,我们发现iPS-HLC中大量产生HBV蛋白和病毒RNA。通过Southern印迹分析在iPS-HLC中检测到了HBV基因组的三种主要形式。抗HBV药物恩替卡韦和Myrcludex-B分别是核苷类似物逆转录酶抑制剂和合成的pre-S1肽,分别显着抑制了iPS-HLC中的HBV感染。这些数据表明,iPS-HLC可用作有希望的体外HBV感染模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号